The cardiac biomarkers market size has grown rapidly in recent years. It will grow from $21.19 billion in 2025 to $24.22 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to increasing incidence of cardiovascular diseases, expansion of emergency cardiac care services, rising adoption of laboratory diagnostics, growing use of biomarker-based diagnosis, improvements in immunoassay technologies.
The cardiac biomarkers market size is expected to see rapid growth in the next few years. It will grow to $42.21 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to increasing demand for rapid cardiac diagnostics, rising adoption of decentralized testing models, expansion of preventive cardiology screening, growing investments in advanced diagnostic platforms, increasing integration of digital health analytics. Major trends in the forecast period include increasing adoption of high-sensitivity troponin tests, rising use of point-of-care cardiac testing, growing demand for rapid diagnostic kits, expansion of multiplex cardiac biomarker panels, enhanced focus on early cardiac risk detection.
The increase in healthcare expenditures is anticipated to drive the growth of the cardiac biomarker market. Healthcare expenditures encompass all costs related to health services, family planning, nutrition programs, and emergency health assistance, with a specific focus on improving health outcomes. Investment in cardiac biomarkers is aimed at enhancing early detection, enabling personalized treatment, and ensuring efficient resource allocation, which can potentially lower the overall costs associated with cardiovascular diseases. For example, a report from the Office for National Statistics, a UK-based government department, indicated that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a mere 0.9% growth in 2022. Consequently, the increase in healthcare expenditures is fueling the expansion of the cardiac biomarker market.
Prominent companies in the cardiac biomarker market are dedicated to developing innovative assays to expand their product portfolios, aiming to enhance patient outcomes and address unmet medical needs. These innovative biomarker assays contribute to advancements in cardiac diagnostics, improving accuracy and diagnostic capabilities. For instance, in October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. launched two new cardiac biomarkers, high-sensitivity troponin I (hs-cTnI) and NT-proBNP. These additions augment Mindray's varied portfolio of cardiac biomarkers, bolstering capabilities in diagnosing and managing cardiovascular diseases (CVDs).
In December 2023, Mindray, a medical devices company based in China, acquired DiaSys Diagnostic Systems GmbH for an undisclosed amount. This acquisition aims to strengthen Mindray's global competitiveness in in vitro diagnostics by integrating DiaSys' capabilities and broadening its international presence. DiaSys Diagnostic Systems GmbH, located in Germany, specializes in the field of in vitro diagnostics.
Major companies operating in the cardiac biomarkers market are F. Hoffmann-La Roche AG, Siemens Healthineers AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Bio-Rad Laboratories Inc, bioMérieux SA, QuidelOrtho Corporation, Randox Laboratories Ltd, Becton Dickinson and Company, Tosoh Corporation, PerkinElmer Inc, Grifols S.A., DiaSorin S.p.A., Sysmex Corporation, Lepu Medical Technology (Beijing) Co. Ltd, Mindray Bio-Medical Electronics Co. Ltd, Fujirebio Holdings Inc, Euroimmun AG, Beckman Coulter Inc, Trinity Biotech plc.
North America was the largest region in the cardiac biomarkers market in 2025. The regions covered in the cardiac biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the cardiac biomarkers market by increasing costs of imported reagents, assay kits, analyzers, and diagnostic instruments used in laboratory and point-of-care testing. Hospitals and diagnostic laboratories in North America and Europe are most affected due to dependence on imported test kits, while Asia-Pacific faces higher costs for manufacturing and exporting diagnostic reagents. These tariffs are increasing testing costs and impacting procurement budgets. However, they are also promoting local reagent manufacturing, regional supply chain diversification, and innovation in cost-optimized cardiac diagnostic solutions.
The cardiac biomarkers market research report is one of a series of new reports that provides cardiac biomarkers market statistics, including cardiac biomarkers industry global market size, regional shares, competitors with a cardiac biomarkers market share, detailed cardiac biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac biomarkers industry. This cardiac biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiac biomarkers represent substances released by the heart into the bloodstream during periods of injury or stress, aiding in the detection and measurement of various cardiac and vascular conditions.
The primary categories of cardiac biomarkers encompass creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA), among others. Creatine kinase (CK) is an enzyme present in multiple body tissues, including muscles and the brain, commonly utilized in diagnosing myocardial infarction (MI), commonly known as a heart attack. These biomarkers find application across diverse testing settings such as point-of-care and laboratory-based assessments. They serve multiple diagnostic purposes, including testing for myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), atherosclerosis, among other cardiac conditions. Hospitals and specialized clinics heavily rely on these biomarkers in their diagnostic protocols.
The cardiac biomarkers market consists of sales of assays and reagents, point-of-care testing (POCT) devices, instruments, and software solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cardiac biomarkers market size is expected to see rapid growth in the next few years. It will grow to $42.21 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to increasing demand for rapid cardiac diagnostics, rising adoption of decentralized testing models, expansion of preventive cardiology screening, growing investments in advanced diagnostic platforms, increasing integration of digital health analytics. Major trends in the forecast period include increasing adoption of high-sensitivity troponin tests, rising use of point-of-care cardiac testing, growing demand for rapid diagnostic kits, expansion of multiplex cardiac biomarker panels, enhanced focus on early cardiac risk detection.
The increase in healthcare expenditures is anticipated to drive the growth of the cardiac biomarker market. Healthcare expenditures encompass all costs related to health services, family planning, nutrition programs, and emergency health assistance, with a specific focus on improving health outcomes. Investment in cardiac biomarkers is aimed at enhancing early detection, enabling personalized treatment, and ensuring efficient resource allocation, which can potentially lower the overall costs associated with cardiovascular diseases. For example, a report from the Office for National Statistics, a UK-based government department, indicated that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a mere 0.9% growth in 2022. Consequently, the increase in healthcare expenditures is fueling the expansion of the cardiac biomarker market.
Prominent companies in the cardiac biomarker market are dedicated to developing innovative assays to expand their product portfolios, aiming to enhance patient outcomes and address unmet medical needs. These innovative biomarker assays contribute to advancements in cardiac diagnostics, improving accuracy and diagnostic capabilities. For instance, in October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. launched two new cardiac biomarkers, high-sensitivity troponin I (hs-cTnI) and NT-proBNP. These additions augment Mindray's varied portfolio of cardiac biomarkers, bolstering capabilities in diagnosing and managing cardiovascular diseases (CVDs).
In December 2023, Mindray, a medical devices company based in China, acquired DiaSys Diagnostic Systems GmbH for an undisclosed amount. This acquisition aims to strengthen Mindray's global competitiveness in in vitro diagnostics by integrating DiaSys' capabilities and broadening its international presence. DiaSys Diagnostic Systems GmbH, located in Germany, specializes in the field of in vitro diagnostics.
Major companies operating in the cardiac biomarkers market are F. Hoffmann-La Roche AG, Siemens Healthineers AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Bio-Rad Laboratories Inc, bioMérieux SA, QuidelOrtho Corporation, Randox Laboratories Ltd, Becton Dickinson and Company, Tosoh Corporation, PerkinElmer Inc, Grifols S.A., DiaSorin S.p.A., Sysmex Corporation, Lepu Medical Technology (Beijing) Co. Ltd, Mindray Bio-Medical Electronics Co. Ltd, Fujirebio Holdings Inc, Euroimmun AG, Beckman Coulter Inc, Trinity Biotech plc.
North America was the largest region in the cardiac biomarkers market in 2025. The regions covered in the cardiac biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the cardiac biomarkers market by increasing costs of imported reagents, assay kits, analyzers, and diagnostic instruments used in laboratory and point-of-care testing. Hospitals and diagnostic laboratories in North America and Europe are most affected due to dependence on imported test kits, while Asia-Pacific faces higher costs for manufacturing and exporting diagnostic reagents. These tariffs are increasing testing costs and impacting procurement budgets. However, they are also promoting local reagent manufacturing, regional supply chain diversification, and innovation in cost-optimized cardiac diagnostic solutions.
The cardiac biomarkers market research report is one of a series of new reports that provides cardiac biomarkers market statistics, including cardiac biomarkers industry global market size, regional shares, competitors with a cardiac biomarkers market share, detailed cardiac biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac biomarkers industry. This cardiac biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiac biomarkers represent substances released by the heart into the bloodstream during periods of injury or stress, aiding in the detection and measurement of various cardiac and vascular conditions.
The primary categories of cardiac biomarkers encompass creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA), among others. Creatine kinase (CK) is an enzyme present in multiple body tissues, including muscles and the brain, commonly utilized in diagnosing myocardial infarction (MI), commonly known as a heart attack. These biomarkers find application across diverse testing settings such as point-of-care and laboratory-based assessments. They serve multiple diagnostic purposes, including testing for myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), atherosclerosis, among other cardiac conditions. Hospitals and specialized clinics heavily rely on these biomarkers in their diagnostic protocols.
The cardiac biomarkers market consists of sales of assays and reagents, point-of-care testing (POCT) devices, instruments, and software solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cardiac Biomarkers Market Characteristics
3. Cardiac Biomarkers Market Supply Chain Analysis
4. Global Cardiac Biomarkers Market Trends and Strategies
5. Cardiac Biomarkers Market Analysis of End Use Industries
7. Global Cardiac Biomarkers Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cardiac Biomarkers Total Addressable Market (TAM) Analysis for the Market
9. Cardiac Biomarkers Market Segmentation
10. Cardiac Biomarkers Market Regional and Country Analysis
11. Asia-Pacific Cardiac Biomarkers Market
12. China Cardiac Biomarkers Market
13. India Cardiac Biomarkers Market
14. Japan Cardiac Biomarkers Market
15. Australia Cardiac Biomarkers Market
16. Indonesia Cardiac Biomarkers Market
17. South Korea Cardiac Biomarkers Market
18. Taiwan Cardiac Biomarkers Market
19. South East Asia Cardiac Biomarkers Market
20. Western Europe Cardiac Biomarkers Market
21. UK Cardiac Biomarkers Market
22. Germany Cardiac Biomarkers Market
23. France Cardiac Biomarkers Market
24. Italy Cardiac Biomarkers Market
25. Spain Cardiac Biomarkers Market
26. Eastern Europe Cardiac Biomarkers Market
27. Russia Cardiac Biomarkers Market
28. North America Cardiac Biomarkers Market
29. USA Cardiac Biomarkers Market
30. Canada Cardiac Biomarkers Market
31. South America Cardiac Biomarkers Market
32. Brazil Cardiac Biomarkers Market
33. Middle East Cardiac Biomarkers Market
34. Africa Cardiac Biomarkers Market
36. Cardiac Biomarkers Market Competitive Landscape and Company Profiles
37. Cardiac Biomarkers Market Other Major and Innovative Companies
40. Cardiac Biomarkers Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Cardiac Biomarkers Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cardiac biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cardiac biomarkers? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiac biomarkers market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Biomarker Type: Creatine Kinase (CK-Mb); Troponins; Myoglobin; Natriuretic Peptides (BNP And NT-proBNP); Ischemia Modified Albumin (IMA)2) By Location Of Testing: Point Of Care Testing; Laboratory Testing
3) By Application: Myocardial Infarction; Congestive Heart Failure; Acute Coronary Syndrome (ACS); Atherosclerosis; Other Applications
4) By End User: Hospitals; Specialty Clinics
Subsegments:
1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits; CK-Mb Diagnostic Panels2) By Troponins: Troponin I Test Kits; Troponin T Test Kits; Troponin Diagnostic Panels
3) By Myoglobin: Myoglobin Test Kits; Myoglobin Diagnostic Panels
4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits; NT-ProBNP Test Kits; Natriuretic Peptides Diagnostic Panels
5) By Ischemia Modified Albumin (IMA): IMA Test Kits; IMA Diagnostic Panels
Companies Mentioned: F. Hoffmann-La Roche AG; Siemens Healthineers AG; Abbott Laboratories; Thermo Fisher Scientific Inc; Danaher Corporation; Bio-Rad Laboratories Inc; bioMérieux SA; QuidelOrtho Corporation; Randox Laboratories Ltd; Becton Dickinson and Company; Tosoh Corporation; PerkinElmer Inc; Grifols S.A.; DiaSorin S.p.A.; Sysmex Corporation; Lepu Medical Technology (Beijing) Co. Ltd; Mindray Bio-Medical Electronics Co. Ltd; Fujirebio Holdings Inc; Euroimmun AG; Beckman Coulter Inc; Trinity Biotech plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cardiac Biomarkers market report include:- F. Hoffmann-La Roche AG
- Siemens Healthineers AG
- Abbott Laboratories
- Thermo Fisher Scientific Inc
- Danaher Corporation
- Bio-Rad Laboratories Inc
- bioMérieux SA
- QuidelOrtho Corporation
- Randox Laboratories Ltd
- Becton Dickinson and Company
- Tosoh Corporation
- PerkinElmer Inc
- Grifols S.A.
- DiaSorin S.p.A.
- Sysmex Corporation
- Lepu Medical Technology (Beijing) Co. Ltd
- Mindray Bio-Medical Electronics Co. Ltd
- Fujirebio Holdings Inc
- Euroimmun AG
- Beckman Coulter Inc
- Trinity Biotech plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 24.22 Billion |
| Forecasted Market Value ( USD | $ 42.21 Billion |
| Compound Annual Growth Rate | 14.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
